Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Provides Update on Beacon Mill Restart and Exploration Updates (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biomarin Pharmaceutical Inc BMRN

Healthcare Biotechnology
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BMRN)

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

PR Newswire 1 day ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

PR Newswire February 25, 2025

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

PR Newswire February 24, 2025

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

PR Newswire February 19, 2025

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

PR Newswire February 5, 2025

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

PR Newswire January 13, 2025

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

PR Newswire January 6, 2025

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

PR Newswire November 16, 2024

BioMarin to Participate in Three Upcoming Investor Conferences

PR Newswire November 6, 2024
View More News ››

Opinion & Analysis (NDAQ:BMRN)

How sick will Brexit make biotech and pharma?

The Life Sciences Report June 29, 2016

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014

Big Pharma has a big problem and merger mania is heating up

Marc Lichtenfeld July 29, 2010
View More Opinion ››

Bullboard Posts (NDAQ:BMRN)

Market Perform Recommendation Issued On BMRN By Bernstein

Breaking News: $BMRN Market Perform Recommendation Issued On BMRN By Bernstein2024-06-04 15:30:03 ET Bernstein analyst issues MARKET...
whytestocks - June 4, 2024

$15 billion biotech stock

there's clearly a wind at the back of this health care company. As a biotech stock that focuses on rare disease gene therapy, BMRN is...
Lisaslab - August 24, 2022

Bulls on Parade

Get ready for the correction; getting close to day 3 
hart.marco - August 21, 2020

Holding Strong

in the face of overall weakness.strong management leads to strong results.great job here!...again,if this was a vancouver,canada bio-tech...
seldomseen1 - March 7, 2008

RE: moving forward

new highs ..here we come.if this was a vancouver biotech(LOL)/managements there would roll this back..they are too funny LOL.
seldomseen1 - February 1, 2008

moving forward

coming off highs,still very strong going forward.
seldomseen1 - January 29, 2008
View more Bullboard ››

Taranis Resources Inc.

Taranis Resources Inc.

Taranis Resources Inc. is a Canadian mineral exploration company. The Company is principally engaged in the acquisition ...
View More »